Welcome to the SYCAMORE Website
The SYCAMORE trial has now stopped recruiting new participants. The Independent Data Safety and Monitoring Committee (IDSMC) have reviewed the data collected so far and have stated that we have enough information from the 90 participants who have taken part so far to suggest that Adalimumab helps to treat patients with Juvenile Idiopathic Arthritis and Uveitis. The independent experts have kept the results confidential until SYCAMORE is finished and all of the data can be looked at. All participants that are currently receiving Adalimumab in the trial will continue to receive trial treatment until they have completed the 18 months treatment phase.
Participants who are taking part in the trial or have taken part can find out more information by looking at the frequently asked questions page here or by speaking to your Doctor.
The map below shows the current hospital sites taking part in the SYCAMORE Trial.
View SYCAMORE Hospital Sites in a full screen map